TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15723746
Drug: Placebo, identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, identical capsules twice daily for 8 weeks
Study: 11879161
Drug: Switch from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch from sertraline to imipramine (mean dosage, 221 mg/d)
Study: 11879161
Drug: Switch from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch from imipramine to sertraline (mean dosage, 163 mg/d)
Study: 11999913
Drug: Sertraline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline treatment
Study: 11001240
Drug: Imipramine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine treatment
Study: 27787890
Drug: Switching treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching treatments
Study: 7798653
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated varicella vaccine (1 dose for children, 2 doses for adults)
Study: 7798653
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated varicella vaccine (2 doses for adults)
Study: 2157637
Drug: Pyrogastrone five
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrogastrone five tablets daily
Study: 397016
Drug: Lidoflazine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidoflazine (120 mg t.i.d. for 9 weeks)
Study: 21484237
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of hydrocortisone (two boluses of 60 mg)
Study: 18926434
Drug: Conivaptan 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conivaptan 40 mg/d
Study: 18926434
Drug: Conivaptan 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conivaptan 80 mg/d
Study: 15076259
Drug: Osmotic, controlled-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osmotic, controlled-release oral system (OROS) MPH (Concerta) given once daily (q.d.)
Study: 15076259
Drug: Immediate-release MPH
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release MPH (Ritalin) given in equal doses three times daily (t.i.d.)
Study: 11302799
Drug: +Calanolide A
Normalized name: Calanolide A
DrugBank: Calanolide A (DB04886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: +Calanolide A (200 mg)
Study: 11302799
Drug: +Calanolide A
Normalized name: Calanolide A
DrugBank: Calanolide A (DB04886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: +Calanolide A (400 mg)
Study: 11302799
Drug: +Calanolide A
Normalized name: Calanolide A
DrugBank: Calanolide A (DB04886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: +Calanolide A (600 mg)
Study: 11302799
Drug: +Calanolide A
Normalized name: Calanolide A
DrugBank: Calanolide A (DB04886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: +Calanolide A (800 mg)
Study: 7880510
Drug: Benzodiazepine agonists
Normalized name: 1,2-Benzodiazepine
DrugBank: 1,2-Benzodiazepine (DB12537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine agonists (midazolam 2.5 mg or diazepam 5 mg)
Study: 7880510
Drug: Thiopental sodium
Normalized name: Thiopental Sodium
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopental sodium 1 mg/kg
Study: 3207438
Drug: Ciclotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclotropium bromide (CTB) administered intravenously
Study: 3207438
Drug: Hyoscine N‐butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine N‐butylbromide (HNB) administered intravenously
Study: 29336700
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein supplement (SPS) 45g (230 Kcal) added to lunch fruit juice
Study: 28612083
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (tamsulosin 0.2 mg/day and trospium chloride 20 mg twice daily)
Study: 28612083
Drug: Monotherapy (tamsulosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (tamsulosin 0.2 mg/day)
Study: 23343197
Drug: Early intensive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intensive cognitive-linguistic therapy (Group A) - one hour a day for four weeks, starting within two weeks after stroke.
Study: 23343197
Drug: Deferred regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred regular therapy (Group B) - professional speech and language therapy deferred for four weeks, followed by conventional therapy.
Study: 16611657
Drug: Interferon gamma-1b
Normalized name: Interferon Gamma-1B
DrugBank: Interferon gamma-1b (DB00033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon gamma-1b (IFN-gamma 1b) administered subcutaneously thrice weekly for 2 years
Study: 12868555
Drug: Irinotecan 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 125 mg/m2 and mitomycin C 5 mg/m2, given every 2 weeks until progression or limiting toxicity.
Study: 9183137
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (1 hour of bright-light therapy plus 2 hours of dawn simulation)
Study: 1550435
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 50 micrograms/min of isosorbide dinitrate (ISDN)
Study: 1550435
Drug: Intravenous N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous N-acetylcysteine at a dosage of 10 g/24 hours
Study: 3902224
Drug: Molsidomine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (2 mg single oral dose)
Study: 15832421
Drug: OAC group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC group (omeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg)
Study: 15832421
Drug: OAM group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAM group (omeprazole 20 mg, amoxicillin 1000 mg, metronidazole 400 mg)
Study: 12953127
Drug: 10 microg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg/kg/day (single dose) G-CSF
Study: 12953127
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 5 microg/kg/day (split dose) G-CSF
Study: 30650624
Drug: Multidimensional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidimensional physical activity intervention (twice a week for 10 weeks)
Study: 22768272
Drug: Daytime energy
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daytime energy intake of ∼150% of estimated daily energy expenditure
Study: 22768272
Drug: Daytime energy
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daytime energy intake of ∼50% of estimated daily energy expenditure
Study: 17868007
Drug: Extended-release dipyridamole
Normalized name: ASPIRIN 25 mg / DIPYRIDAMOLE 200 mg ORAL CAPSULE, EXTENDED RELEASE [ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release dipyridamole plus aspirin
Study: 11260535
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg nickel
Study: 11260535
Drug: 3.0 mg
Normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg nickel
Study: 8391064
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus thoracic radiotherapy (TRT)
Study: 8391064
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (CAV)
Study: 8391064
Drug: Consolidation chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation chemotherapy (cisplatin and etoposide)
Study: 3555049
Drug: Ciprofloxacin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (250 mg orally, twice daily)
Study: 3555049
Drug: Cinoxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinoxacin (500 mg orally, twice daily)
Study: 23453352
Drug: Glucomannan (GM)
DrugBank: Konjac mannan (DB14963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucomannan (GM) combined with low-dose chromium-polynicotinate (CP)
Study: 23453352
Drug: Glucomannan (GM)
DrugBank: Konjac mannan (DB14963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucomannan (GM) combined with low-dose policosanol (PC)
Study: 20636352
Drug: V-Taper Ni-Ti
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: V-Taper Ni-Ti rotary and stainless steel hand instruments
Study: 19026310
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose steroids and cyclosporine
Study: 11086179
Drug: Mitoxantrone 36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 36 mg/m2 on day 1
Study: 11086179
Drug: Mitoxantrone 45
Normalized name: mitoXANTRONE 45 MG per 22.5 ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 45 mg/m2 on day 1
Study: 11086179
Drug: Mitoxantrone 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 60 mg/m2 on day 1
Study: 11086179
Drug: Mitoxantrone 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 75 mg/m2 on day 1 with cytarabine 500 mg/m2 and etoposide 200 mg/m2
Study: 11086179
Drug: EMA chemotherapy
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMA chemotherapy (mitoxantrone, cytarabine, etoposide)
Study: 8804872
Drug: Glutamine glucose
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine glucose salt solution
Study: 8804872
Drug: Alanine glucose
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alanine glucose salt solution
Study: 24578607
Drug: Cervical interlaminar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical interlaminar epidural injections of local anesthetic (lidocaine 0.5%, 5 mL)
Study: 22859902
Drug: Cervical interlaminar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical interlaminar epidural injections of local anesthetic (0.5% lidocaine, 4 mL) mixed with 1 mL of nonparticulate betamethasone
Study: 8953684
Drug: imipenem/cilastatin 1.5-2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: imipenem/cilastatin 1.5-2.0 g/day
Study: 8953684
Drug: cefuroxime 3.0-4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefuroxime 3.0-4.5 g/day plus metronidazole 1.0-1.5 g/day
Study: 2007851
Drug: Endotoxin/ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endotoxin/ibuprofen
Study: 27628742
Drug: Parent‐Focused Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent‐Focused Treatment (PFT)
Study: 26021246
Drug: Ranolazine 500
Normalized name: ranolazine 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine 500 mg bid for 3 months
Study: 23129778
Drug: Ki-67 index
Normalized name: KI
DrugBank: Potassium Iodide (DB06715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ki-67 index guided preoperative chemotherapy (paclitaxel and trastuzumab initially, modified based on Ki-67 index)
Study: 23129778
Drug: Standard preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preoperative chemotherapy (paclitaxel and trastuzumab)
Study: 23129778
Drug: Ki-67 index
Normalized name: KI
DrugBank: Potassium Iodide (DB06715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ki-67 index guided preoperative chemotherapy
Study: 23129778
Drug: Standard preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preoperative chemotherapy
Study: 17352304
Drug: Additional anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional anticoagulant treatment for patients found to have thrombophilia
Study: 17352304
Drug: Standard predefined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard predefined duration of treatment for others
Study: 9792572
Drug: LT receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: LT receptor antagonist (pranlukast, 450 mg/d)
Study: 9792572
Drug: TXA2 synthetase
Normalized name: nitric oxide synthase
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA2 synthetase inhibitor (ozagrel, 800 mg/d)
Study: 9792572
Drug: TXA2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA2 receptor antagonist (seratrodast, 80 mg/d)
Study: 7825976
Drug: BEAM association
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEAM association (BCNU + etoposide + high dose aracytine + high dose melphalan)
Study: 27299675
Drug: Empagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (10 mg or 25 mg once daily)
Study: 24334183
Drug: Pioglitazone (PIO;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (PIO; 30 mg/d)
Study: 18510207
Drug: Nutrition intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition intervention package (weekly 30-minute sessions for 7 weeks)
Study: 16630304
Drug: Clinpro Cario
Normalized name: Clinpro 5000
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clinpro Cario L-Pop (CCLP) test
Study: 7076369
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose of methadone
Study: 7076369
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of methadone
Study: 7076369
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of methadone
Study: 29672533
Drug: i-gel with
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-gel with cup-type respirator
Study: 24136928
Drug: PHEN/TPM ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHEN/TPM ER 7.5/46 mg
Study: 24136928
Drug: PHEN/TPM ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHEN/TPM ER 15/92 mg
Study: 24136928
Drug: Phentermine 7.5
Normalized name: phentermine 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine 7.5 mg
Study: 24136928
Drug: Phentermine 15
Normalized name: phentermine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine 15 mg
Study: 24136928
Drug: Topiramate ER
Normalized name: Topiramate ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate ER 46 mg
Study: 24136928
Drug: Topiramate ER
Normalized name: Topiramate ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate ER 92 mg
Study: 8672620
Drug: Other antibiotics
Normalized name: Other antibiotics for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antibiotics
Study: 10607766
Drug: Placebo (physiologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (physiologic sodium chloride solution)
Study: 9193328
Drug: Epirubicin 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 120 mg/m2 and Cyclophosphamide 700 mg/m2 every 21 days
Study: 9193328
Drug: Epirubicin 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 75 mg/m2 and Cyclophosphamide 500 mg/m2 every 10 days
Study: 9193328
Drug: Epirubicin 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 75 mg/m2 and Cyclophosphamide 500 mg/m2 every 8 days
Study: 27265742
Drug: Bavituximab 3
Normalized name: Bavituximab
DrugBank: Bavituximab (DB05136)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bavituximab 3 mg/kg
Study: 27265742
Drug: Placebo/Bavituximab 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/Bavituximab 1 mg/kg
Study: 22355055
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for high-grade gliomas
Study: 16205837
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg for 22 days
Study: 1476025
Drug: Injections of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections of allergen-antibody complexes made of D. pteronyssinus allergens and specific autologous antibodies.
Study: 6220672
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg
Study: 3157008
Drug: Trimethoprim-sulfamethoxazole 160
Normalized name: sulfamethoxazole
DrugBank: Sulfamethoxazole (DB01015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole 160 mg and 800 mg respectively, twice daily for 10 days
Study: 24676651
Drug: Intravenous metamizole
Normalized name: Metamizole
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metamizole 1.5 g every 8 h during the first 24 postoperative hours
Study: 24676651
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol 1 g every 8 h during the first 24 postoperative hours
Study: 12039127
Drug: Adenosine-receptor blocker
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine-receptor blocker 8-sulfophenyltheophylline
Study: 7911143
Drug: Lumen used
Normalized name: Luden's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumen used for repeat infusions and injections
Study: 7911143
Drug: Lumen permanently
Normalized name: Luden's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumen permanently connected to slow infusion of 0.9% NaCl
Study: 22113647
Drug: Increased daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased daily water intake by 1.5 l
Study: 20413122
Drug: Po-husk (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Po-husk (14 g/d)
Study: 20413122
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg/d) added to Po-husk or placebo
Study: 29349980
Drug: Arthroscopic debridement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic debridement with continuous irrigation using sensitive antibiotics for 2-3 weeks
Study: 21488521
Drug: Inpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient treatment as usual (Control group, n=11)
Study: 14982865
Drug: Pharmacare restricted
Normalized name: hypromellose
DrugBank: Hypromellose (DB11075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacare restricted reimbursement for nebulised bronchodilators, steroids, and cromoglycate with individual patient exemptions.
Study: 10962052
Drug: Metronidazole (3x400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (3x400 mg orally per day), mesalazine (3x1 g orally per day), and betamethasone enema (once a day during 4 weeks)
Study: 3662563
Drug: Generic formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic formulations of triamcinolone acetonide, fluocinolone acetonide, and betamethasone valerate
Study: 15715531
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ferrous iron
Study: 15715531
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ferrous iron
Study: 15715531
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg ferrous iron
Study: 15715531
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg ferrous iron
Study: 10357371
Drug: SQV‐SGC 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQV‐SGC 1200 mg three times per day
Study: 10357371
Drug: Indinavir 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir 800 mg three times per day
Study: 1709781
Drug: Intraumbilical vein
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraumbilical vein administration of 10 IU of oxytocin in 20 ml of saline solution
Study: 6165817
Drug: Intrasulcular brushing
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrasulcular brushing technique for 30 seconds daily for 49 days
Study: 6165817
Drug: Extrasulcular brushing
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extrasulcular brushing technique for 30 seconds daily for 49 days
Study: 15057739
Drug: Ciprofloxacin (CIP)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin (CIP) 2 x 400 mg/day + Metronidazole (MET) 2 x 500 mg/day
Study: 11182039
Drug: Doxifluridine 600
Normalized name: Trifluridine
DrugBank: Trifluridine (DB00432)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Doxifluridine 600 mg/body/day (group A)
Study: 11182039
Drug: Doxifluridine 800
Normalized name: Trifluridine
DrugBank: Trifluridine (DB00432)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Doxifluridine 800 mg/body/day (group B)
Study: 9270458
Drug: 10 day
Normalized name: DexPak 10 Day Taperpak
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 day prescription of antibiotics
Study: 9270458
Drug: Delayed prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed prescription if sore throat had not started to settle after three days
Study: 9270458
Drug: Antibiotics prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics prescribed for sore throat during the previous year
Study: 9270458
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics or delayed prescription
Study: 8173754
Drug: WEB 2086
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: WEB 2086 40 mg three times daily for 12 weeks
Study: 2906380
Drug: Sydnocarb (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sydnocarb (10 mg X 2 in air or 30 mg X 5 in water)
Study: 2906380
Drug: Sydnogluton (sydnocarb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sydnogluton (sydnocarb 30 mg + glutamic acid 0.25 g X 5 in cold water)
Study: 2179222
Drug: Sildimac (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildimac (new drug delivery system for silver sulfadiazine)
Study: 2179222
Drug: Silvadene cream
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silvadene cream 1% (twice-daily wound cleansing)
Study: 28159782
Drug: Tenapanor (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenapanor (3 or 30 mg once daily or 1, 3, 10, or 30 mg twice daily)
Study: 26115513
Drug: sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: sertraline plus mirtazapine
Study: 19571597
Drug: sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: sertraline plus placebo
Study: 24176228
Drug: Baobab fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baobab fruit extract (18.5 g and 37 g)
Study: 11977360
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment
Study: 17320021
Drug: Selective estrogen
Normalized name: Selective estrogen receptor modulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective estrogen receptor modulators (SERMs) such as raloxifene